Serious adverse events · Ménière’s disease
It is very uncertain whether betahistine changes serious adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Serious adverse events · people with vestibular migraine
It is very uncertain whether beta‐blockers changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · adults with PPPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Ménière’s disease
It is very uncertain whether intratympanic corticosteroids changes serious adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Serious adverse events · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with vestibular migraine
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with acute attacks of vestibular migraine
1 finding from 1 review
Serious adverse events · adults with PPPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with PPPD
1 finding from 1 review
Serious adverse events · adults with PPPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
Serious adverse events · patients with chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IgE mAb (omalizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) may leads to lower serious adverse events compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review